UA111161C2 - Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування - Google Patents
Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосуванняInfo
- Publication number
- UA111161C2 UA111161C2 UAA201301524A UAA201301524A UA111161C2 UA 111161 C2 UA111161 C2 UA 111161C2 UA A201301524 A UAA201301524 A UA A201301524A UA A201301524 A UAA201301524 A UA A201301524A UA 111161 C2 UA111161 C2 UA 111161C2
- Authority
- UA
- Ukraine
- Prior art keywords
- derivative
- preparation
- phtalasinoncetone
- pharmaceutical application
- pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Похідна фталазинонкетону, що представлена формулою (І), спосіб її одержання, фармацевтична композиція, що містить похідну, її використання як інгібітора полі(АДФ-рибоза)полімерази (ПАРП) та спосіб лікування нею раку.(I)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102483075A CN102372716A (zh) | 2010-08-09 | 2010-08-09 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
PCT/CN2011/001223 WO2012019427A1 (zh) | 2010-08-09 | 2011-07-26 | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
UA111161C2 true UA111161C2 (uk) | 2016-04-11 |
Family
ID=45567315
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA201301524A UA111161C2 (uk) | 2010-08-09 | 2011-07-26 | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування |
Country Status (16)
Country | Link |
---|---|
US (2) | US9273052B2 (uk) |
EP (1) | EP2604610B1 (uk) |
JP (1) | JP5808408B2 (uk) |
KR (1) | KR101829940B1 (uk) |
CN (2) | CN102372716A (uk) |
AU (1) | AU2011288876B2 (uk) |
BR (1) | BR112013002220B1 (uk) |
CA (1) | CA2806324C (uk) |
ES (1) | ES2582315T3 (uk) |
HK (1) | HK1174030A1 (uk) |
HU (1) | HUE029275T2 (uk) |
PL (1) | PL2604610T3 (uk) |
PT (1) | PT2604610T (uk) |
RU (1) | RU2564527C2 (uk) |
UA (1) | UA111161C2 (uk) |
WO (1) | WO2012019427A1 (uk) |
Families Citing this family (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102898377B (zh) * | 2012-02-14 | 2016-01-20 | 南京圣和药业股份有限公司 | 一类酞嗪酮衍生物及其用途 |
CN102702108A (zh) * | 2012-06-27 | 2012-10-03 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
CN102863393A (zh) * | 2012-09-26 | 2013-01-09 | 上海大学 | 1,2-二氢酞嗪类化合物及其合成方法 |
BR112015012425A2 (pt) * | 2012-12-31 | 2017-07-11 | Cadila Healthcare Ltd | composto, composição farmacêutica, método e medicamento para o tratamento de doenças medicadas pela proteína parp-1 e uso do composto |
KR101670126B1 (ko) | 2013-09-13 | 2016-10-27 | 일동제약(주) | 신규 프탈라지논 유도체 및 그 제조방법 |
AR098414A1 (es) | 2013-11-14 | 2016-05-26 | Bristol Myers Squibb Co | PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e |
CN108138177B9 (zh) | 2015-07-23 | 2021-08-13 | 法国居里学院 | Dbait分子与PARP抑制剂的组合用于治疗癌症的用途 |
CN106749261A (zh) | 2015-11-23 | 2017-05-31 | 中国科学院上海药物研究所 | 一类取代三唑并哌嗪类parp抑制剂及其制备方法和用途 |
WO2017101796A1 (zh) * | 2015-12-16 | 2017-06-22 | 四川科伦博泰生物医药股份有限公司 | 酞嗪酮衍生物、其制备方法及用途 |
US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
EP3549608A4 (en) | 2016-12-01 | 2020-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | USE OF A COMBINATION OF A VEGFR INHIBITOR AND PARP INHIBITOR IN THE MANUFACTURING OF A MEDICINAL PRODUCT FOR TREATMENT OF STOMACH CANCER |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
RS60209B1 (sr) | 2017-03-20 | 2020-06-30 | Forma Therapeutics Inc | Kompozicije pirolopirola kao aktivatori piruvat kinaze (pkr) |
JP6977058B2 (ja) * | 2017-04-12 | 2021-12-08 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピクテ・スペングラー反応を介して得られたタグ付けヌクレオシドを用いたシーケンシング反応のための方法 |
ES2915830T3 (es) | 2017-08-24 | 2022-06-27 | Jiangsu Hengrui Medicine Co | Forma cristalina del inhibidor de parp-1 y procedimiento de preparación del mismo |
JP2021505548A (ja) * | 2017-12-06 | 2021-02-18 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 化学療法抵抗性の卵巣がんまたは乳がんの治療におけるparp阻害剤の使用 |
WO2019137358A1 (zh) | 2018-01-09 | 2019-07-18 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂及其中间体的制备方法 |
EA202091787A1 (ru) * | 2018-01-26 | 2020-11-06 | Рекордати Индустрия Кимика Э Фармасеутика С.П.А | ТРИАЗОЛ-, ИМИДАЗОЛ- И ПИРРОЛ-КОНДЕНСИРОВАННЫЕ ПИПЕРАЗИНОВЫЕ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ mGLu5 РЕЦЕПТОРОВ |
EP3758695A4 (en) * | 2018-02-28 | 2021-10-06 | The Trustees Of The University Of Pennsylvania | POLY (AD-RIBOSE) DEPENDENT CYTOTOXIC AGENTS LOW AFFINITY POLYMERASE-1 |
US20200407720A1 (en) | 2018-03-13 | 2020-12-31 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
RU2020131507A (ru) * | 2018-03-29 | 2022-05-04 | Боард Оф Реджентс, Де Юниверсити Оф Техас Систем | Имидазопиперазиновые ингибиторы белков-активаторов транскрипции |
WO2020061255A1 (en) | 2018-09-19 | 2020-03-26 | Forma Therapeutics, Inc. | Activating pyruvate kinase r |
US20220031671A1 (en) | 2018-09-19 | 2022-02-03 | Forma Therapeutics, Inc. | Treating sickle cell disease with a pyruvate kinase r activating compound |
CN112584836A (zh) * | 2018-10-22 | 2021-03-30 | 江苏恒瑞医药股份有限公司 | 一种ar拮抗剂联合parp抑制剂在制备治疗前列腺癌的药物中的用途 |
CN115645370A (zh) * | 2018-11-16 | 2023-01-31 | 江苏恒瑞医药股份有限公司 | 一种包含parp抑制剂的药物组合物 |
WO2020238932A1 (zh) * | 2019-05-28 | 2020-12-03 | 江苏恒瑞医药股份有限公司 | Parp抑制剂联合vegfr抑制剂用于治疗卵巢癌或乳腺癌的用途 |
CN112870365A (zh) * | 2019-11-29 | 2021-06-01 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
MX2022013304A (es) | 2020-04-21 | 2022-12-15 | Idience Co Ltd | Formas cristalinas de compuesto de ftalazinona. |
CN111732594B (zh) * | 2020-08-18 | 2022-03-04 | 苏州富士莱医药股份有限公司 | 一种氟唑帕利的制备方法 |
JP2024519188A (ja) * | 2021-05-24 | 2024-05-08 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | 含窒素複素環系化合物、その調製方法及びその医薬的応用 |
WO2023288002A1 (en) * | 2021-07-16 | 2023-01-19 | Oregon Health & Science University | Phthalazinone-based parp-1 inhibitors |
EP4378938A1 (en) * | 2021-07-29 | 2024-06-05 | Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. | Novel parp7 inhibitor and use thereof |
CN115650988A (zh) * | 2022-10-27 | 2023-01-31 | 江苏恒瑞医药股份有限公司 | 一种parp抑制剂的制备方法 |
WO2024109871A1 (zh) * | 2022-11-23 | 2024-05-30 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1330442B1 (en) | 2000-10-30 | 2011-01-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
EP1477175B1 (en) * | 2002-02-19 | 2011-04-27 | Ono Pharmaceutical Co., Ltd. | Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient |
AR043443A1 (es) | 2003-03-07 | 2005-07-27 | Merck & Co Inc | Procedimiento de preparacion de tetrahidrotriazolopirazinas y productos intermedios |
PL1633724T3 (pl) * | 2003-03-12 | 2011-10-31 | Kudos Pharm Ltd | Pochodne ftalazynonu |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
JP2008510783A (ja) | 2004-08-26 | 2008-04-10 | クドス ファーマシューティカルズ リミテッド | 4−ヘテロアリールメチル置換フタラジノン誘導体 |
GB0610680D0 (en) * | 2006-05-31 | 2006-07-12 | Istituto Di Ricerche D Biolog | Therapeutic compounds |
CN103690542B (zh) * | 2006-12-28 | 2015-11-18 | Abbvie公司 | 聚(adp-核糖)聚合酶抑制剂 |
US20090023727A1 (en) * | 2007-07-05 | 2009-01-22 | Muhammad Hashim Javaid | Phthalazinone derivatives |
EP2190428A4 (en) | 2007-08-21 | 2012-02-29 | Merck Sharp & Dohme | HETEROCYCLIC COMPOUNDS AS DIPEPTIDYLPEPTIDASE-IV INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES |
CN101468988A (zh) | 2007-12-26 | 2009-07-01 | 上海恒瑞医药有限公司 | 哌嗪类衍生物,其制备方法及其在医药上的应用 |
JP2011509962A (ja) | 2008-01-17 | 2011-03-31 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 置換スルホンアミド誘導体 |
-
2010
- 2010-08-09 CN CN2010102483075A patent/CN102372716A/zh active Pending
-
2011
- 2011-07-26 BR BR112013002220-5A patent/BR112013002220B1/pt active IP Right Grant
- 2011-07-26 CN CN201180003990.9A patent/CN102686591B/zh active Active
- 2011-07-26 RU RU2013106754/04A patent/RU2564527C2/ru active
- 2011-07-26 CA CA2806324A patent/CA2806324C/en active Active
- 2011-07-26 US US13/811,957 patent/US9273052B2/en active Active
- 2011-07-26 EP EP11815986.2A patent/EP2604610B1/en active Active
- 2011-07-26 AU AU2011288876A patent/AU2011288876B2/en active Active
- 2011-07-26 JP JP2013523468A patent/JP5808408B2/ja active Active
- 2011-07-26 UA UAA201301524A patent/UA111161C2/uk unknown
- 2011-07-26 ES ES11815986.2T patent/ES2582315T3/es active Active
- 2011-07-26 PL PL11815986.2T patent/PL2604610T3/pl unknown
- 2011-07-26 PT PT118159862T patent/PT2604610T/pt unknown
- 2011-07-26 WO PCT/CN2011/001223 patent/WO2012019427A1/zh active Application Filing
- 2011-07-26 KR KR1020137003185A patent/KR101829940B1/ko active IP Right Grant
- 2011-07-26 HU HUE11815986A patent/HUE029275T2/en unknown
-
2013
- 2013-01-23 HK HK13101036.9A patent/HK1174030A1/xx unknown
-
2016
- 2016-02-05 US US15/016,986 patent/US9566277B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102372716A (zh) | 2012-03-14 |
PL2604610T3 (pl) | 2016-11-30 |
HUE029275T2 (en) | 2017-02-28 |
CA2806324A1 (en) | 2012-02-16 |
BR112013002220B1 (pt) | 2021-09-21 |
AU2011288876A1 (en) | 2013-01-31 |
ES2582315T3 (es) | 2016-09-12 |
EP2604610A4 (en) | 2013-12-25 |
US20160151367A1 (en) | 2016-06-02 |
US9566277B2 (en) | 2017-02-14 |
BR112013002220A2 (pt) | 2016-05-24 |
WO2012019427A8 (zh) | 2012-05-10 |
US20130131068A1 (en) | 2013-05-23 |
EP2604610A1 (en) | 2013-06-19 |
CA2806324C (en) | 2019-02-19 |
KR20130110149A (ko) | 2013-10-08 |
CN102686591B (zh) | 2014-03-19 |
WO2012019427A1 (zh) | 2012-02-16 |
KR101829940B1 (ko) | 2018-02-19 |
RU2013106754A (ru) | 2014-09-20 |
EP2604610B1 (en) | 2016-05-11 |
AU2011288876A2 (en) | 2013-02-21 |
HK1174030A1 (en) | 2013-05-31 |
PT2604610T (pt) | 2016-07-13 |
CN102686591A (zh) | 2012-09-19 |
JP5808408B2 (ja) | 2015-11-10 |
US9273052B2 (en) | 2016-03-01 |
AU2011288876B2 (en) | 2014-08-21 |
RU2564527C2 (ru) | 2015-10-10 |
JP2013535491A (ja) | 2013-09-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA111161C2 (uk) | Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування | |
PH12020550552A1 (en) | Inhibitors of hepatitis c virus | |
PH12017502141A1 (en) | Compounds and their methods of use | |
GEP201706624B (en) | Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment | |
PH12015501996B1 (en) | Heterocyclic compounds and uses thereof | |
EA201301209A1 (ru) | Производные пирролотриазинона в качестве ингибиторов p13k | |
WO2012019426A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
CO6321282A2 (es) | Derivados de piperidinilindol como inhibidores de aldosterona sintasa | |
DK2922828T3 (da) | 4,6-diamino-pyrimidin-derivater som bmi-1-inhibitorer til at behandle cancer | |
WO2011153157A3 (en) | Benzoquinolone inhibitors of vmat2 | |
WO2012019430A8 (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
MA34064B1 (fr) | Compose heterocyclique | |
UA111744C2 (uk) | ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk | |
GEP20156372B (en) | Pyridazinone compounds and their use as daao inhibitors | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
GEP201706623B (en) | Pyrrolotriazinone derivatives as pi3k inhibitors | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
PH12015501175A1 (en) | Substituted pyridopyrazines as syk inhibitors | |
EA201590561A1 (ru) | Пролекарства аминохиназолинового ингибитора киназы | |
UY34314A (es) | Derivados de anilina, su preparación y su aplicación terapéutica. | |
PH12015502032A1 (en) | Azetidinyloxyphenylpyrrolidine compounds | |
WO2011123524A3 (en) | Macrolide inhibitors of mtor | |
EA201590656A1 (ru) | Азаиндолины | |
CL2011002930A1 (es) | Compuestos derivados de 8-oxo-9-[3-(1h-bencimidazol-2-iloxi)-fenil]-4,5,6,7,8,9-hexahidro-2h-pirrolo[3,4-b]quinolina-3-carboxilato de etilo; procedimiento de preparacion; composicion farmaceutica que lo comprende; compuestos intermediarios; y uso del compuesto como inhibidor selectivo de quinasas aurora a y b para tratar el cancer. |